Attached files
| file | filename |
|---|---|
| EX-99.1 - Molecular Templates, Inc. | v206391_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 22, 2010 (December 22,
2010)
THRESHOLD
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-32979
|
94-3409596
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
1300
Seaport Boulevard, Suite 500
Redwood
City, California 94063
(Address
of principal executive offices)(Zip Code)
(650)
474-8200
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
On
December 22, 2010, Threshold Pharmaceuticals, Inc. issued a press release
announcing early clinical trial results related to Threshold’s clinical stage
hypoxia-activated prodrug, TH-302 in patients with advanced leukemias, and a
preclinical collaboration to study TH-302 in leukemia. The press
release is attached as Exhibit 99.1 to this Form 8-K.
|
Item 9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits
|
|
Exhibit 99.1
|
Press
release dated December 22,
2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
THRESHOLD
PHARMACEUTICALS, INC.
|
||
|
By:
|
/s/ Joel A.
Fernandes
|
|
|
Joel
A. Fernandes
|
||
|
|
Senior
Director, Finance and
Controller
|
|
Date: December
22, 2010
Exhibit
Index
|
Exhibit No.
|
Description
|
|
|
Exhibit
99.1
|
|
Press
release dated December 22,
2010.
|